Experimental HER2 cancer drug trial halted early
NCT ID NCT05514717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was an early-phase study testing a new drug called XMT-2056 in people with advanced solid tumors that have a protein called HER2. The trial aimed to find a safe dose and check for side effects. It was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XMT-2056 (given intravenously)
What this could lead to
If it had succeeded, this could have pointed toward a new treatment option for advanced HER2-positive cancers.
What could go wrong
The trial was terminated early, so results are limited. It was a very early phase 1 study, so safety and effectiveness were not established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Celebration
Celebration, Florida, 34747, United States
-
Emory Healthcare, Emory Clinic
Atlanta, Georgia, 30322, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
New York University Medical Oncology Associates
New York, New York, 10016, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43212, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of South California
Los Angeles, California, 90033, United States